2023 World Conference on Lung Cancer (Posters)-P2.06. Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3

P2.06. Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3 - PDF(Abstract)

Back to course

Pdf Summary

This presentation discusses the use of cemiplimab, an anti-programmed cell death-1 (PD-1) antibody, as a treatment for advanced non-small cell lung cancer (NSCLC) with liver metastases. The study analyzed the efficacy and safety of cemiplimab monotherapy and cemiplimab combination treatments compared to chemotherapy in patients with liver metastases at baseline.<br /><br />The analysis included data from two phase 3 trials: EMPOWER-Lung 1 and EMPOWER-Lung 3 Part 2. The results showed that cemiplimab treatment demonstrated longer overall survival (OS) and progression-free survival (PFS) compared to chemotherapy in patients with liver metastases. Cemiplimab also had a higher objective response rate (ORR) compared to chemotherapy. These trends of improvement were observed in both trials.<br /><br />The safety profile of cemiplimab treatment was found to be generally comparable between patients with and without baseline liver metastases.<br /><br />Overall, the longer-term results of the study continue to demonstrate the clinical benefit of cemiplimab monotherapy and cemiplimab combination treatments over platinum-based chemotherapy in patients with liver metastases from advanced NSCLC.<br /><br />This study provides valuable evidence on the effectiveness and safety of cemiplimab as a treatment option for patients with advanced NSCLC and liver metastases.

Asset Subtitle

Ana Baramidze

Meta Tag

Speaker Ana Baramidze

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

cemiplimab

anti-programmed cell death-1 antibody

advanced non-small cell lung cancer

NSCLC

liver metastases

efficacy

safety

chemotherapy

overall survival

progression-free survival